Kailera Therapeutics, Inc. (KLRA)

Kailera Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024
Period Ending	Dec 31, 2025	Dec 31, 2024
Cash & Equivalents	160.27	175.18
Short-Term Investments	385.79	-
Cash & Short-Term Investments	546.06	175.18
Cash Growth	211.72%	-
Other Receivables	2.73	-
Receivables	2.73	-
Prepaid Expenses	7.52	2.09
Other Current Assets	1.23	0.34
Total Current Assets	557.54	177.61
Property, Plant & Equipment	12.42	0.68
Long-Term Investments	106.67	-
Long-Term Deferred Charges	2.6	0.15
Other Long-Term Assets	13.07	-
Total Assets	692.29	178.45
Accounts Payable	7.53	2.01
Accrued Expenses	36.92	2.23
Current Portion of Leases	1.04	0.51
Other Current Liabilities	0.92	2.16
Total Current Liabilities	46.41	6.91
Long-Term Leases	9.71	-
Other Long-Term Liabilities	0.27	-
Total Liabilities	56.39	6.91
Additional Paid-In Capital	11.98	0.94
Retained Earnings	-368.67	-219.71
Comprehensive Income & Other	0.23	-
Total Common Equity	-356.46	-218.77
Shareholders' Equity	635.91	171.53
Total Liabilities & Equity	692.29	178.45
Total Debt	10.75	0.51
Net Cash (Debt)	641.98	174.67
Net Cash Growth	267.54%	-
Net Cash Per Share	33703.01	-
Filing Date Shares Outstanding	0.02	-
Total Common Shares Outstanding	0.02	-
Working Capital	511.13	170.7
Book Value Per Share	-18713.67	-
Tangible Book Value	-356.46	-218.77
Tangible Book Value Per Share	-18713.67	-
Machinery	1.49	0.26
Leasehold Improvements	0.56	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q